The Association of TNF-Alpha Inhibitors and Development of IgA Nephropathy in Patients with Rheumatoid Arthritis and Diabetes.
Journal
Case reports in nephrology
ISSN: 2090-6641
Titre abrégé: Case Rep Nephrol
Pays: United States
ID NLM: 101598418
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
08
2019
accepted:
25
01
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
epublish
Résumé
IgA nephropathy (IgAN) is a rather uncommon complication of TNF-alpha inhibition with a range of findings such as asymptomatic microscopic/macroscopic hematuria or different degrees of proteinuria and could progress to end-stage renal disease. We are reporting three patients with longstanding rheumatoid arthritis (RA), which developed IgAN while receiving TNF-alpha inhibitors. All off our three patients had RA, which lasted 2-4 years, and none of them had a prior history of chronic kidney disease. Two patients were treated with adalimumab while one patient was treated with golimumab. Discontinuation of anti-TNF-alpha therapy and initiation of immunosuppressive therapy led to improvement in serologic abnormalities and renal function in two patients, while the third patient's 24-hour proteinuria was only partially reduced, which supports previous reports on TNF-alpha inhibitor induced autoimmunity. Two of our patients had previously been diagnosed with type 2 diabetes mellitus while the third patient developed diabetes years after the onset of IgAN. This is in line with the previously described association of IgAN and diabetes mellitus. To our best knowledge, this is the first report to analyze the development of IgAN as a potential consequence of anti-TNF-alpha therapy and its possible association with pretreatment or posttreatment diabetes.
Identifiants
pubmed: 32373375
doi: 10.1155/2020/9480860
pmc: PMC7191367
doi:
Types de publication
Case Reports
Langues
eng
Pagination
9480860Commentaires et corrections
Type : ErratumIn
Laganovic, Mario; Željkovic-Vrkic, Tajana; Kos, Jelena [added]
Informations de copyright
Copyright © 2020 Vedran Premužić et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this article.
Références
Clin Nephrol. 2004 Sep;62(3):234-8
pubmed: 15481857
Clin Nephrol. 2001 Jan;55(1):87-8
pubmed: 11200876
Neth J Med. 2003 Apr;61(4):137-41
pubmed: 12852723
Drug Saf. 2004;27(5):307-24
pubmed: 15061685
Chin Med J (Engl). 2015 Sep 20;128(18):2555-6
pubmed: 26365982
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
J Rheumatol. 2004 Oct;31(10):1955-8
pubmed: 15468359
Kidney Int. 2017 May;91(5):1014-1021
pubmed: 28341274
Lancet. 2002 Feb 16;359(9306):579-80
pubmed: 11867114
Autoimmun Rev. 2014 Aug;13(8):873-9
pubmed: 24840285
Ann Rheum Dis. 2004 Sep;63(9):1075-8
pubmed: 15066863
Am J Kidney Dis. 1992 Sep;20(3):255-60
pubmed: 1519606
Nephrol Dial Transplant. 2005 Jul;20(7):1400-6
pubmed: 15840673
Case Rep Nephrol. 2013;2013:812781
pubmed: 24558628
Mod Rheumatol. 2002 Jun;12(2):148-54
pubmed: 24383903
Diabetes Res Clin Pract. 2000 May;48(2):113-8
pubmed: 10802148